|

Romiplostim N01 Clinical Trials

8 actively recruiting trials

▲ +1 trial since June 2026

Also known as: N01, TPO receptor agonist, Thrombopoietin receptor agonist

Pipeline

Phase 1: 1Phase 2: 6Phase 3: 1

Top Sponsors

  • Peking University People's Hospital2
  • Anhui Provincial Hospital2
  • The First Affiliated Hospital with Nanjing Medical University1
  • Institute of Hematology & Blood Diseases Hospital, China1
  • First Affiliated Hospital of Zhejiang University1

Indications

  • Cancer8
  • Chemotherapy-induced Thrombocytopenia4
  • Persistent Isolated Chemotherapy-Induced Thrombocytopenia2
  • Cancer Treatment-induced Thrombocytopenia (CTIT)1
  • Hematological Tumor1

Other8 trials

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
Phase 3
Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia
Phase 2
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Phase 2
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Phase 2
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Phase 2
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
Phase 2
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
Phase 1
Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.